malek

1338 Words6 Pages
1. Dave, D., & Saffer, H. (2012). Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand. Southern Economic Journal, 79(1), 97-126. Retrieved November 11, 2013, from http://web.ebscohost.com.ezp1.lib.umn.edu/ehost/detail?sid=3d4ba3e1-10ba-4c42-ba37-18cca35f5bef%40sessionmgr10&vid=1&hid=24&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=keh&AN=79748769 This article examines the impact of DTCA expansion on pharmaceutical expenditures, sales, and prices. The main findings are that broadcast DTCA have more influence on sales and prices than non-broadcast DTCA, and are responsible for the majority of a drug company's advertising expenditures. This paper will help to support our statement regarding DTCA issues in the grant proposal. The findings suggest that our focus should be directed towards stricter regulation of broadcast DTCA because it is the media which drug company can use to manipulate consumers and convince them to choose their products. Thus, the risk of bias information will be higher for drug ads over media. 2. Federal Trade Commission. (2003). Ftc staff provides fda with comments on direct-to-consumer prescription advertising. Federal Trade Commission. Retrieved November 12, 2013, from http://www.ftc.gov/be/v040002text.pdf This paper discusses suggestions which the Federal Trade Commission can make to the FDA in regards to regulation of DTC Advertising, and how the FDA can change the regulations in ways that DTCA will offer unbiased information and delivers content which is understandable to consumers. This reference is very helpful because it gives us ideas for establishing rules and requirements for broadcast ads and how the FTC can collaborate with the FDA in DTCA regulation. 3. Greene, J A, Choudhry, N... ... middle of paper ... ...r advertising. Clinical therapeutics, 23(12), 2024-37. Retrieved November 10, 2013, from http://tc.liblink.umn.edu/sfx_local?sid=Entrez%3APubMed&id=pmid%3A11813936&issn=0149-2918 This paper examines how FDA regulates DTCA in broadcast media, and encourages utilization of DTCA because it informs patients available treatments in the market. Also, the authors argue that consumers should be able to become involved directly in choosing their own treatments. The FDA needs to offer guidance based on the foundation that advertising needs to offer unbiased information. It is an important article for our proposal because it provides evidences of how DTCA is beneficial to public and supports the idea that FDA needs to regulate DTCA in a way that all medical information should be free from bias which help customers become more confident in choosing their therapeutic options.

More about malek

Open Document